GlycoVue Ltd

GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based instrumentation to create a platform for diabetes self-management. We have fabricated a transparent glucose-sensitive hologram using in-house synthesised boronate monomers as the selective glucose receptors. Preliminary in vitro assessment of its sensitivity, stability and performance appears promising. A smartphone is used to quantify the colour response of the hologram with an appropriate algorithm and convert it into the blood glucose concentration. GlycoVue has the potential to revolutionise diabetes management by launching a glucose measurement system which would potentially lead to better adherence to glucose self-monitoring and therefore ameliorate the complications of diabetes. This will improve the life quality of >425M people with diabetes and potentially halve diabetes-related healthcare costs. The glucose self-monitoring market is expected to reach US$32.3B by 2024 with a CAGR of 6.2% from 2016. Our team covers expertise across the value chain, is well-balanced and autonomous, and has unique complementary skills to deliver and exploit the technology.